HomeCONGRESS

CONGRESS

View Category
Day 2

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve...
solaci -
Learn More
Day 2

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device...
solaci -
Learn More
Day 2

PROTAVI-C: Embolic protection during TAVI

Percutaneous aortic valve replacement (TAVI) is a new treatment option for patients that are inoperable or present...
solaci -
Learn More
Day 2

EXPAND: expanding the applications of bioresorbable platforms

There is little information about the use of bioresorbable vascular devices in patients with a reference diameter...
solaci -
Learn More
Day 2

BuMA stent: new sirolimus-eluting stent with bio-degradable polymer

Uncovered struts compromise re-endothelization and may induce thrombosis. The new stent approved in China and already used...
solaci -
Learn More
Day 2

PROMUS PREMIER: new everolimus-eluting stent

The study aims to evaluate clinical, angiographic and IVUS results of the new platinum chromium everolimus stent....
solaci -
Learn More
Day 2

PRAGUE 19: bioabsorbable platform for patients with ST segment elevation

Absorbable bioplatforms are considered safe and effective in stable patients but their use in the context of...
solaci -
Learn More
Day 2

POLAR ACS: bio-absorbable platform in acute coronary syndromes

Bio-absorbable devices are considered safe and effective for stable patients but there is still little information regarding...
solaci -
Learn More